Comparative effectiveness of combined antiplatelet treatments in acute minor ischaemic stroke
- Authors
- Kim, Shina; Kim, Joon-Tae; Lee, Ji Sung; Kim, Beom Joon; Park, Jong-Moo; Kang, Kyusik; Lee, Soo Joo; Kim, Jae Guk; Cha, Jae-Kwan; Kim, Dae-Hyun; Park, Tai Hwan; Park, Sang-Soon; Lee, Kyung Bok; Lee, Jun; Hong, Keun-Sik; Cho, Yong-Jin; Park, Hong-Kyun; Lee, Byung-Chul; Yu, Kyung-Ho; Oh, Mi Sun; Kim, Dong-Eog; Ryu, Wi-Sun; Choi, Jay Chol; Kwon, Jee-Hyun; Kim, Wook-Joo; Shin, Dong-Ick; Sohn, Sung-Il; Hong, Jeong-Ho; Park, Man-Seok; Choi, Kang-Ho; Cho, Ki-Hyun; Lee, Juneyoung; Bae, Hee-Joon
- Issue Date
- Feb-2022
- Publisher
- BMJ Publishing Group
- Keywords
- stroke
- Citation
- Stroke and Vascular Neurology, v.7, no.1, pp 13 - 21
- Pages
- 9
- Indexed
- SCIE
SCOPUS
- Journal Title
- Stroke and Vascular Neurology
- Volume
- 7
- Number
- 1
- Start Page
- 13
- End Page
- 21
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54917
- DOI
- 10.1136/svn-2020-000841
- ISSN
- 2059-8688
2059-8696
- Abstract
- Background
No study has thoroughly compared the effectiveness of combined antiplatelet treatments (other than clopidogrel–aspirin) versus clopidogrel–aspirin or aspirin alone for early secondary prevention in acute ischaemic stroke.
Methods
We identified patients with acute, minor, non-cardiogenic ischaemic stroke treated with aspirin alone, clopidogrel–aspirin or other combination treatment. Propensity scores considering the inverse probability of treatment weighting were used to adjust for baseline imbalances. The primary outcome was the composite of all strokes (ischaemic or haemorrhagic), myocardial infarction and all-cause mortality at 3 months.
Results
Among 12 234 patients (male: 61.9%; age: 65.5±13 years) who met the eligibility criteria, aspirin, clopidogrel–aspirin and other combination treatments were administered in 52.2%, 42.9% and 4.9% of patients, respectively. In the crude analysis, the primary outcome event at 3 months occurred in 14.5% of the other combination group, 14.4% of the aspirin group and 13.0% of the clopidogrel–aspirin group. In the weighted Cox proportional hazards analysis, the 3-month primary outcome event occurred less frequently in the clopidogrel–aspirin group than in the other combination group (weighted HR: 0.82 (0.59–1.13)), while no association was found between the aspirin group (weighted HR: 1.04 (0.76–1.44)) or other combination group and the 3-month primary outcome.
Conclusion
Other combined antiplatelet treatment, compared with aspirin alone or clopidogrel–aspirin, was not associated with reduced risks of primary composite vascular events or recurrent stroke during the first 3 months after stroke. Therefore, the results suggest that other combination treatments, particularly the cilostazol-based combination, may not be effective alternatives for clopidogrel–aspirin to prevent early vascular events in patients with acute minor stroke. Further exploration in clinical trials will be needed.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 1. Basic Science > Department of Biostatistics > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.